ISM 3312
Alternative Names: 3-chymotrypsin-like protease inhibitor - Insilico Medicine; 3CL Mpro inhibitor - Insilico Medicine; 3CL protease inhibitor - InSilico Medicine; 3CLpro inhibitor; ISM-3312Latest Information Update: 28 Jun 2026
At a glance
- Originator InSilico Medicine
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C protease inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jun 2026 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (PO)
- 28 Apr 2026 No recent reports of development identified for phase-I development in COVID-2019-infections in China (PO)
- 07 Oct 2025 Insilico Medicine completes phase-I clinical trials in COVID-2019 infections in China (PO) (Insilico Medicine Pipeline, October 2025)